title: Incidence of stent thrombosis in patients with drug eluting stents and short-term dual antiplatelet therapy.
abstract: OBJECTIVE
  This study sought to investigate the incidence of stent thrombosis (ST) in patients treated with drug-eluting stents (DES) and clearly defined short-term dual antiplatelet therapy (DAT) for three or six months for sirolimus-eluting stents (SES) or paclitaxel-eluting stents (PES), respectively.
  
  
  RESULTS
  A series of 1023 consecutive patients with 1,414 stented lesions and prescribed short-term DAT were followed for at least two years after DES implantation. The individual durations of DAT, the rate of ischaemic events, and survival status were assessed. Follow-up was completed for 1017 patients (99.4%) with a mean follow-up of 3.0 +/- 0.7 years. DAT duration was 2.8 +/- 0.4 and 5.9 +/- 0.8 months in patients with SES and PES, respectively. Adherence to continued single antiplatelet therapy was 98.4%. We identified 14 patients with definite ST (1.4%) and no patients with probable ST with a cumulative incidence of 0.6% at 30 days, of 0.8% at one year, of 1.2% at 2 years, and of 1.4% at three years.
  
  
  CONCLUSIONS
  Definite or probable ST after DES implantation and short DAT occurs with a cumulative incidence of 1.4% at 3 years if excellent patient adherence to the continued single antiplatelet therapy can be achieved.
authors.affiliation: Cardiovascular Division, City Hospital Linz, Linz, Austria. clemens.steinwender@akh.linz.at
authors.forename: Clemens
authors.initials: C
authors.lastname: Steinwender
authors.forename: Bernhard
authors.initials: B
authors.lastname: Hartenthaler
authors.forename: Thomas
authors.initials: T
authors.lastname: Lambert
authors.forename: Alexander
authors.initials: A
authors.lastname: Kypta
authors.forename: Jürgen
authors.initials: J
authors.lastname: Kammler
authors.forename: Simon
authors.initials: S
authors.lastname: Hönig
authors.forename: Robert
authors.initials: R
authors.lastname: Hofmann
authors.forename: Klaus
authors.initials: K
authors.lastname: Kerschner
authors.forename: Franz
authors.initials: F
authors.lastname: Leisch
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015906:Angioplasty, Balloon, Coronary / Q000009:adverse effects* / Q000295:instrumentation*; D001241:Aspirin / Q000008:administration & dosage*; D002317:Cardiovascular Agents / Q000008:administration & dosage; D000077144:Clopidogrel; D003324:Coronary Artery Disease / Q000628:therapy*; D019992:Databases as Topic; D004334:Drug Administration Schedule; D054855:Drug-Eluting Stents; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D015994:Incidence; D053208:Kaplan-Meier Estimate; D008297:Male; D055118:Medication Adherence; D008875:Middle Aged; D017239:Paclitaxel / Q000008:administration & dosage; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage*; D020123:Sirolimus / Q000008:administration & dosage; D013927:Thrombosis / Q000453:epidemiology / Q000209:etiology* / Q000517:prevention & control; D013988:Ticlopidine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D002317:Cardiovascular Agents; D010975:Platelet Aggregation Inhibitors; D000077144:Clopidogrel; D013988:Ticlopidine; D017239:Paclitaxel; D001241:Aspirin; D020123:Sirolimus